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Essentially all cellular processes are orchestrated by protein-protein interactions (PPIs). In
recent years, afﬁnity puriﬁcation coupled to mass spectrometry (AP-MS) has been the
preferred method to identify cellular PPIs. Here we present a microﬂuidic-based AP-MS
workﬂow, called on-chip AP-MS, to identify PPIs using minute amounts of input material. By
using this automated platform we purify the human Cohesin, CCC and Mediator complexes
from as little as 4 micrograms of input lysate, representing a 50─100-fold downscaling
compared to regular microcentrifuge tube-based protocols. We show that our platform can
be used to afﬁnity purify tagged baits as well as native cellular proteins and their interaction
partners. As such, our method holds great promise for future biological and clinical AP-MS
applications in which sample amounts are limited.
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Identiﬁcation and characterisation of protein–protein interac-tions (PPIs) is a major focus area in biology. A variety ofapproaches have been developed to study PPIs, such as yeast
two-hybrid screening, co-immunoprecipitation combined with
western blots and phage display1,2.
During the last 2 decades, afﬁnity puriﬁcation mass spectro-
metry (AP-MS) has proven to be a powerful technology to
elucidate protein–protein interactions in cells and tissues3–5.
Antibodies targeting native proteins can be used to investigate
protein interactions on a large scale6. When highly speciﬁc
antibodies are not available, epitope tagging is an attractive
alternative for AP-MS. In addition, complementary approaches
to identify PPIs have been developed, such as proximity labeling
technologies7–9. In all these studies, up to milligrams of lysates
isolated from millions of cells are used for each afﬁnity pur-
iﬁcation. For this reason, AP-MS screenings are typically per-
formed on immortalized cells such as cancer cell lines which can
easily be grown in very large quantities and which can be
genetically manipulated10,11.
In recent years it has become apparent that PPIs and their
dynamics are important during development12. Furthermore,
perturbed PPIs play critical roles in establishing disease pheno-
types (e.g., in amyloidosis)13–16. Therefore, it is increasingly
important to identify PPIs in near-physiological models (i.e., in
organoids or early embryonic tissue) and in clinical samples.
Those specimens are often available in limited quantities and are
therefore not applicable for interaction proteomics studies.
Here, we describe a microﬂuidic-based AP-MS platform called
on-chip AP-MS which facilitates PPI studies from as little as
12,000 input cells, representing a 50–100-fold downscaling
compared to regular microcentrifuge tube-based workﬂows. We
benchmark our method using a number of well-characterized
mammalian protein complexes, which we puriﬁed from green
ﬂuorescent protein (GFP)-tagged HeLa cells. In addition, we
provide evidence that our platform can be used to purify cellular
protein complexes using antibodies against native proteins.
Results
Developing and benchmarking on-chip AP-MS. To explore the
input limitations of microcentrifuge-based AP-MS workﬂows, we
performed preliminary afﬁnity puriﬁcation experiments using
transgenic HeLa Kyoto cell lines expressing SMC1A as a GFP
fusion protein at near-endogenous levels using BAC Transge-
neOmics17. SMC1A is a subunit of the human Cohesin complex,
which plays an important role in chromosome segregation, DNA
repair, and transcriptional regulation. In the presence of ATP,
SMC1A forms a heterodimer with SMC3. The SMC1A/SMC3
dimer interacts with RAD21 and STAG1/2 to form a stable
Cohesin ring around DNA18. We puriﬁed SMC1A-GFP from a
range of input lysates starting from 500 μg of whole cell extract
down to 4 μg. As a negative control, we used wild-type HeLa
Kyoto cells. These experiments revealed that decreasing the
amount of input lysate in microcentrifuge tube-based afﬁnity
puriﬁcation workﬂows results in a gradual loss of performance
and detection of interaction partners. At the lowest titration
point, 4 µg of input whole-cell extract, detection of almost all
interaction partners is lost (Supplementary Figure 1, Supple-
mentary Data 1). These results illustrate the urgent need to
develop alternative AP-MS protocols that are compatible with
low-input sample amounts. Previous studies have made initial
steps in this direction, for example, by establishing AP-MS pro-
tocols on 96-well ﬁlter plates, but those approaches still require
several hundreds of micrograms of input lysate19–21.
We set out to develop an AP-MS workﬂow that enables robust
detection of PPIs from small amounts of whole-cell lysate. To
achieve this, we took advantage of an analog microﬂuidic system
containing puriﬁcation columns to perform afﬁnity puriﬁcations
followed by on-bead protein digestion (Fig. 1). This all occurs in
very small volumes (nanoliter scale) and in a fully automated
manner, thereby reducing variation between experiments.
Notably, the development of the protocol involved assessing
compatibility of reagents22 and afﬁnity puriﬁcation steps with the
microﬂuidic platform. To allow loading of the samples in the
microﬂuidics channels and/or subsequent washing of the
columns on the microﬂuidic platform, we incorporate two
important adaptations as compared to regular pull-down
protocols: exclusion of glycerol as cryoprotectant in the extract
preparation and removal of ethidium bromide as competitor for
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Fig. 1 Workﬂow for afﬁnity puriﬁcation of GFP-tagged complexes on a
microﬂuidic device. A limited number of cells (in this paper we used 12,000
cells for proof-of-principle) expressing a GFP-tagged form of a protein of
interest (PI) are lysed to obtain whole cell extracts that serve as pools of
proteins. Test samples as well as the appropriate controls are loaded into a
microﬂuidic chip which is preloaded with all buffers and reagents that are
required during the IP and preparation of the samples for the LC–MS/MS.
During the microﬂuidic run, columns of GFP-nanobody beads are packed in
single reactors and subsequently washed before loading of the protein
samples from the inlet onto the columns. Tagged macromolecular
assemblies are retained on the GFP-nanobody bead columns and digested
to peptides. Peptide eluates are recovered and prepared for mass
spectrometry analysis, after which speciﬁc interactors are identiﬁed
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protein–DNA interactions in extract incubation with the beads.
We call this method on-chip AP-MS.
To benchmark the on-chip AP-MS method, we made use of the
before-mentioned SMC1A-GFP cell line and wild-type HeLa
Kyoto cells as control. Whole-cell extracts from these cell lines
(4 µg per pull-down in triplicate) were loaded by pressure-driven
laminar ﬂow on a prototypical microﬂuidic chip containing 24
parallel columns packed with beads covered with epoxy groups
functionalized with an in-house puriﬁed GFP nanobody23. After
loading lysates, columns were washed to remove background
proteins, after which column-bound proteins were on-bead
digested with trypsin. The resulting peptide mixtures were then
recovered from the microﬂuidic chip and subjected to liquid
chromatography–tandem mass spectrometry (LC–MS/MS) ana-
lysis on a high-performance hybrid Orbitrap mass spectrometer.
A label-free quantiﬁcation method with t test-based statistics was
used for interactor identiﬁcation. As shown in Fig. 2a, loading
4 µg of SMC1A-GFP extract obtained from bulk preparation of
cells on the microﬂuidics chip yielded all known core Cohesin
subunits as statistically signiﬁcant interaction partners (Fig. 2a,
Supplementary Data 2). To probe for sensitivity, we prepared
whole-cell extracts from different amounts of input cells and then
loaded 4 µg of extract from these preparations on the micro-
ﬂuidics chip. We did not detect a loss in sensitivity when
decreasing the number of input cells (Supplementary Figure 2,
Supplementary Data 3). We were even able to detect all core
SMC1A interactors starting from ~12 × 103 input cells, roughly
equivalent to 4 µg of whole-cell extract, per afﬁnity puriﬁcation
(Fig. 2b; individual replicates in Supplementary Figure 3,
Supplementary Data 4). Importantly, the puriﬁed complex from
these low-input samples showed a similar stoichiometry com-
pared to regular afﬁnity puriﬁcations performed with 500 µg of
input lysate (Fig. 2c; individual replicates in Supplementary
ﬁgure 3). However, it should be noted that even though
we identiﬁed well-characterized Cohesin complex interactors
(WAPL, PDS5A/PDS5B) as substoichiometric SMC1A-GFP
interactors when using 500 μg of input lysate (Supplementary
Figure 1), these proteins are not identiﬁed in low input SMC1A-
GFP pull-downs. Based on these results we conclude that our
low-input AP-MS method has its limitations regarding the ability
to detect low-abundant substoichiometric (<0.1 relative to the
bait) and/or dynamic interactions between core subunits and
regulatory proteins for any given protein complex, depending on
the stoichiometry, afﬁnity, and copy number of the bait and its
interaction partners.
On-chip AP-MS on low-abundant complexes. Cohesin is an
abundant nuclear complex, with the four most prominent sub-
units expressed between 2.8 × 105 and 4 × 105 protein copies per
cell10. To further investigate the sensitivity of our microﬂuidic
platform, we tested whether a lower abundant complex contain-
ing more subunits could be successfully identiﬁed. The coiled-coil
domain-containing protein 93 (CCDC93) is present at ~65 × 103
copies per cell10. CCDC93 is part of the CCC complex composed
of COMMD proteins, CCDC22 and CCDC9324. The CCC
complex, residing in the cytosol and recruited to endosomes by
FAM21, regulates copper trafﬁcking25. By performing on-chip
AP-MS on CCDC93-GFP expressing cells, we identiﬁed all
known CCC complex members as signiﬁcant interaction partners,
both by using 4 µg of whole-cell extract from a large bulk
extraction and from 12 × 103 input cells per pull-down (Fig. 2d, e;
individual replicates in Supplementary Figure 3, Supplementary
Datas 5 and 6). The stoichiometry of these interactions are largely
in line with values obtained using conventional high-input
workﬂows10 (Fig. 2f).
To further benchmark our on-chip AP-MS workﬂow we
puriﬁed the Mediator complex, a very large, well-characterized
complex (~1.4 MDa) involved in gene regulation26,27. Mediator
complex subunits are expressed at cellular copy numbers ranging
from ~850 to 95 × 103 in HeLa cells10. We puriﬁed the Mediator
complex from CDK8-GFP (copy number ~38 × 103 per cell10)
expressing HeLa Kyoto cells using 25 × 103 input cells per pull-
down. We retrieved essentially all (>25) human Mediator
subunits as statistically signiﬁcant CDK8 interactors, albeit at
lower stoichiometry as compared to high-input workﬂows10
(Fig. 3a, b, Supplementary Data 7). Based on these results we
conclude that, whereas our on-chip-AP-MS workﬂow is able to
conﬁdently identify PPIs for relatively low-abundant baits and
interaction partners, stoichiometry estimations for these interac-
tions are more challenging. Nevertheless, these three examples
illustrate that we established a microﬂuidic-based AP-MS
platform that requires ~50–100-fold less input extract than
conventional workﬂows and is thus compatible with clinical
samples or rare cell types that are only available in very small
quantities. To illustrate this, we puriﬁed the GFP-fused mitotic
spindle checkpoint protein BUBR1-GFP from 12 × 103 G2/M
sorted cells, and identiﬁed its dimerization partner, BUB3
(Supplementary Figure 4, Supplementary Data 8). Using a
conventional puriﬁcation strategy and in the absence of any
drugs to arrest cells in mitosis, this would have required at
least 107 input cells per technical replicate.
Expanding the applicability of on-chip AP-MS. For increased
throughput, reduced loading times and the capability of using a
larger array of buffers to facilitate more complex AP-MS work-
ﬂows, we performed the GFP-SMC1A and GFP-CCDC93 afﬁnity
puriﬁcations on a redesigned microﬂuidic chip with 48 parallel
reactors and obtained similar results (Supplementary Figure 5,
Supplementary Data 9). We further used this platform to purify
protein complexes using antibodies against endogenous proteins
in conjunction with protein A/G beads. We were able to purify
SMC1A-GFP using a polyclonal GFP antibody rather than a GFP
nanobody, indicating that our workﬂow can be used to
purify endogenous protein complexes as well (Fig. 4a). To further
support these observations, we also puriﬁed the human
Cohesin complex from HeLa Kyoto cells using an antibody
targeting native endogenous SMC3 (Fig. 4b, Supplementary
Data 10). The performance of these endogenous protein pull-
downs will obviously greatly depend on the antibody afﬁnity and
speciﬁcity, and the abundance of the protein complex. The cur-
rent workﬂow can be conveniently applied on the commercial
Fluidigm C1 platform, as exempliﬁed in this study. We anticipate
that the protocol presented here can also be easily adapted to
other programmable microﬂuidic platforms with a similar design,
namely nanoliter-sized afﬁnity puriﬁcation columns targeting
tagged, proximity labeled or native proteins with pressure-driven
laminar ﬂow of buffers and lysates. However, it should be noted
that the design of the chips that we employed for our experiments
requires using beads with a size between 2 and 10 μm. This
currently excludes the use of some commonly utilized afﬁnity
resins, such as Streptactin28, and Flag/HA, as these are not
available in this size range at this point in time29.
Discussion
With on-chip AP-MS we made important and much-needed
steps to facilitate AP-MS for low-input samples, namely
microﬂuidics-based miniaturization and automation. However,
further improvements to the workﬂow, including direct cell lysis
in the microﬂuidic chip and coupling of the chip to the LC of the
mass spectrometer might further reduce input requirements and
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Fig. 2 Benchmark for on-chip AP-MS on low amounts of total extract using SMC1A-GFP and CCDC93-GFP baits. a, b Volcano plots from label-free
microﬂuidic pull-downs for SMC1A-GFP bait using 4 µg (a) or 12,000 cells (b). The enrichment of the bait and its partners as fold enrichment LFQ GFP over
LFQ control (x-axis) is plotted against the −log10 transformed P value of the permutation based FDR corrected t test (y-axis). ID refers to the total number
of proteins reported and FE stands for fold enrichment. Dotted gray lines represent statistical cut-offs. Black dots identify signiﬁcant proteins; red dots are
signiﬁcant proteins that are known interactors of the bait. HSD17B10 is a known contaminant of pull-downs using Dynabeads®33. Each volcano plot
presents n= 2 biologically independent experiments, each comprised of n= 3 technical replicates for PI-GFP and control extract. c Stoichiometry of the
Cohesin subunits as compared to SMC1A for the experiments shown in panels a and b, as well as a 500 µg microcentrifuge tubes-based pull-down shown
as gold standard (data from Supplementary ﬁgure 1a). iBAQ values for each of the interaction partners of Cohesin were divided by the iBAQ values of the
bait, so that is set to 1. Data display mean values ± s.d. Gray bars represent the stoichiometry of Cohesin complex as derived from for the 4 μg input
experiment, yellow bars for the 12,000 cells input experiment and light blue bars for the 500 μg input microcentrifuge tubes-based pull-down. Black dots
represent the individual data points. d, e Volcano plot from microﬂuidic pull-down for CCDC93-GFP bait using 4 µg (d) and 12,000 cells (e). Dotted gray
lines represent statistical cut-offs. Black dots identify signiﬁcant proteins; red dots are signiﬁcant proteins that are known interactors of the bait. MYO1E
and MYO1C are known contaminants33. ID refers to the total number of proteins reported and FE stands for fold enrichment. Each volcano plot presents
n= 2 biological replicates, each comprised of n= 3 technical replicates for PI-GFP and control extract. f Stoichiometry of the CCC complex subunits as
compared to CCDC93 for the experiments shown in panels (d) and (e), using the pull-down performed by Hein et al.10 as reference. iBAQ values for each
of the CCC interaction partners were divided by the iBAQ values of the bait (set to 1). Data display mean values ± s.d. Gray bars represent the
stoichiometry of CCC complex as derived from the 4 μg experiment, yellow bars for the 12,000 cells experiment and light blue bars for microcentrifuge
tube-based pull-down performed by Hein et al.10. Black dots represent the individual data points. Source data are provided as a Source Data ﬁle
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hands-on time, while increasing robustness and sensitivity of our
on-chip AP-MS workﬂow. Altogether, we envision that the
technology that we present here and improvements thereof could,
in principle, be applied to even lower cell numbers or, eventually,
single cells. In any case, with the development of on-chip AP-MS,
the ﬁeld of mass spectrometry-based interaction proteomics is
taking the next step towards applications in biology and medi-
cine, which thus far, due to technical constraints, have remained
elusive.
Methods
Cell culture and whole cell extract preparation. For preparing the extract for on-
chip AP-MS, HeLa Kyoto WT and BAC lines expressing a C-terminal LAP tagged
form of SMC1A, CCDC93 and CDK8 were obtained from the Hyman laboratory
(Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany)
by courtesy of Dr. Ina Poser. Cells were cultured in high-glucose Dulbecco’s
modiﬁed Eagle medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) and 100 U/mL penicillin and streptomycin. BAC lines were kept under
selection by addition of 400 µg/µL geneticin (G418). All reagents for cell culture
were purchased from Gibco, Life Technologies™. Cells were harvested by trypsi-
nization and centrifuged at 400×g for 5 min at 4 °C. Cell pellets were washed once
in PBS. An aliquot of cells was stained with Trypan Blue 0.4% (Sigma Aldrich,
Merck) and counted on an automated cell counter (TC10™, BioRad or Countess II,
Invitrogen, Thermo Fisher Scientiﬁc). The number of cells required was pipetted
into a 0.5 or 1.5 mL Protein LoBind tube (Eppendorf) and centrifuged again for 5
min at 400×g at 4 °C. PBS was removed using a 30 g needle connected to a vacuum
aspiration system. Cells were lysed in a buffer containing 150 mM NaCl, 50 mM
Tris-HCl pH 8, 1 mM MgCl2, 250 U/mL Benzonase® (Novagen, Millipore), EDTA-
free complete proteins inhibitors (Roche®), and 1% NP-40, 1 mM DTT.
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Fig. 3 Benchmark of on-chip AP-MS with Mediator complex. a Volcano plot from label-free microﬂuidic pull-down for CDK8-GFP bait using 25,000 cells.
Dotted gray lines represent statistical cut-offs. Black dots identify signiﬁcant proteins; red dots are used for known interactors of the bait. ID refers to the
total number of proteins reported and FE stands for fold enrichment. The volcano plot presents n= 1 biologically independent experiment, each comprised
of n= 3 technical replicates for PI-GFP and control extract. b Stoichiometry of the mediator subunits as compared to CDK8 for the experiments using the
same pull-down performed by Hein et al.10 as reference. iBAQ values for each of the interaction partners of Mediator complex were divided by the iBAQ
values of the bait (CDK8, set to 1). Data display mean values ± s.d. Gray ﬁlled bars are used for representing the Mediator complex stoichiometry as
obtained by the 25,000 cells input experiment while yellow bars describe the stoichiometry for Mediator obtained by the microcentrifuge tube-based pull-
down performed by Hein et al.10. Black dots represent the individual data points. Source data are provided as a Source Data ﬁle
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Lysis was performed using (i) 1 µL of buffer per 25,000 cells; or (ii) 1 µL of lysis
buffer for extracting cell numbers lower than 25,000 cells. Samples were incubated
at 4 °C for 2 h rotating (or rocking for low-volume samples) on a Intelli-Mixer RM-
2L program uu60 (Elmi). The extracts were spun at 4000×g for 30 min at 4 °C.
When extracting a large batch of cells, the supernatant was collected without the
lipid layer. Cleared lysates were transferred to another tube and adjusted to a ﬁnal
volume of 2.5 µL with lysis buffer. To further eliminate aggregates, lysates were
spun down 2 min at 18,800 × g at 4 °C on a table centrifuge right before they were
loaded onto the microﬂuidic device. Protein concentration for bulk lysates obtained
from a large number of cells was assessed using a BCA assay (Thermo Fisher
Scientiﬁc). The equivalent of 4 µg of proteins was loaded using a 2.5 µL volume.
For preparing the extract for microcentrifuge tube-based pull-downs, cells were
washed in PBS and harvested as previously described. Pellets were resuspended in 5
cell pellet volumes of lysis buffer containing 150 mM NaCl, 50 mM Tris-HCl pH 8,
1 mM EDTA, 20% glycerol, EDTA-free complete proteins inhibitors (Roche), 1%
NP-40, and 1 mM DTT. Lysates were incubated at 4 °C for 2 h on a rotating wheel
and subsequently centrifuged for 30 min at 4000×g at 4 °C. The supernatant was
collected and snap-frozen in liquid nitrogen.
Cell culture and sorting. HeLa-FlpIn TRex cells expressing LAP-BUBR1 obtained
from the Kops laboratory (Hubrecht Institute, Utrecht, The Netherlands) were
grown in the same conditions as the HeLa BAC lines but puromycin (1 µg/mL)
was used to maintain selection. Cells were induced for ~48 h with doxycyclin
(1 µg/mL). For cell cycle sorting based on DNA content, 8–9 × 106 of induced and
not induced cells were harvested and stained in medium with 5 µM Hoechst 33342
(Thermo Scientiﬁc) for 60 min at 37 °C. Cells were centrifuged at 400×g and
resuspended in PBS containing 1% FBS at a concentration 30 × 106 cells/mL.
Shortly before sorting, cells were strained on a 70 µm sterile Syringe Filcons (BD
biosciences). Sorting was performed on a BD FACSAria instrument and 12 × 103
cells were collected in tubes containing 200 µL of PBS–1% FBS. Lysates were
prepared as above-mentioned.
Puriﬁcation of anti-GFP nanobodies. Puriﬁcation of the lysine free anti-GFP
nanobody (Lag16-2K/R) was performed as previously described17. Brieﬂy, plasmid
containing the Lag16-2K/R nanobody sequence was transformed into Arctic
Express (DE3) competent cells. Transformed bacteria were grown overnight in LB
containing 100 µg/ml ampicillin and 20 µg/ml gentamicin (Sigma G1272). Totally,
10 ml of the overnight culture was used to expand the culture to OD600 0.6 in 1 l LB
containing 100 µg/ml ampicillin. Nanobody expression was induced by 0.1 mM
Isopropil-β-D-1-tiogalattopiranoside at 12 °C for ~24 h. Cells were then harvested
by centrifugation and periplasmic extract was prepared incubating the pellet with
TES buffer (0.2 M Tris-HCl pH 8, 0.5 mM EDTA, 0.5 M sucrose) for 30 min on ice.
Extract was cleared by sequential centrifugations ﬁrstly for 15 min at 4500×g and
secondly for 30 min at 38,800×g. Final supernatant was conditioned to 0.15 M
NaCl and incubated for 30 min at 4 °C with 2 ml of HIS-Select® Nickel Afﬁnity Gel
(Sigma-Aldrich®, P6611) previously washed with water and equilibrated with wash
buffer I (20 mM sodium phosphate buffer pH 8, 0.9 M NaCl). After incubation the
resin was initially washed with 6 volumes of wash buffer I, then with 6 volumes of
wash buffer II (20 mM sodium phosphate buffer pH 8, 0.15 M NaCl, 10 mM
imidazole pH 8) and ﬁnally His-puriﬁed nanobody was eluted with 4 column
volumes of elution buffer (20 mM sodium phosphate buffer pH 8, 0.15 M NaCl,
250 mM imidazole pH 8). Eluted nanobody was dialyzed overnight in PBS in a
Slide-A-Lyzer™ G2 Dialysis Cassettes, 10 K MWCO, 5–15 mL (Thermo Fisher
Scientiﬁc, 87,731). Finally, nanobody was concentrated using a Centriprep Cen-
trifugal Filter Unit 3 kDa cutoff, 15 mL volume (Millipore, 4303).
Chemical coupling of anti-GFP nanobodies to magnetic beads. Chemical con-
jugation of the anti-GFP nanobody to epoxyl Dynabeads® M-270 beads (Invitro-
gen, Thermo Fisher Scientiﬁc) was performed as previously described22. Brieﬂy, 10
mg of epoxyl Dynabeads® M-270 beads were conjugated with 100 µg Lag16-2K/R
anti-GFP nanobody. Beads were washed for 15 min with 0.1 M sodium phosphate
buffer pH 7.4 and for 5 min with 0.1 M sodium phosphate buffer pH 8 rocking.
Antibody mix was prepared by adding 100 µg nanobody, 0.1 M sodium phosphate
buffer pH 8–200 µl ﬁnal volume and 1M ammonium sulfate in 0.1 M sodium
sulfate pH 7.4 (added dropwise). Antibody mix was centrifuged at maximum speed
on a bench top centrifuge for 5 min before being added to the washed beads.
Antibody mix and beads were incubated ~20 h at 30 °C tilted-rotating in a round
bottom 2ml microcentrifuge tube. After incubation conjugated beads were washed
with 100 mM glycine pH 2.5, 10 mM Tris-HCl pH 8.8 and 100 mM triethylamine
freshly prepared to quench the reaction, wash away unbound nanobody and block
unreacted epoxyl groups on the beads. Finally, anti-GFP conjugated beads were
washed with PBS for 5 min 4 times, with 0.5% NP40 in PBS one time for 5 min and
a second time for 15 min rocking, and with PBS for 5 min before storage at −20 °C
in 30% glycerol and 0.02% sodium azide in PBS until further use.
Antibody-based GFP or endogenous protein pull-down. Extracts from 12 × 103
cells were prepared as previously described. Two microlitre of extract were incu-
bated with 180 ng of GFP antibody (HPLC puriﬁed Abcam Ab290: Ab6556) or
Rabbit Control IgG (Abcam 46540, Lot.GR63822-2, ChIP grade). Extracts from
HeLa Kyoto cells were incubated with anti-SMC3 antibody (Abcam Ab9263, ChIP
grade) or normal rabbit IgG (Santa Cruz sc-2027) at 90 ng/4 µg antibody/extract
ratio. Extract and antibody were incubated for 1 h at 4 °C before proceeding with
loading into the microﬂuidics device.
GFP pull-down protocol on microﬂuidic device. Two types of poly-
dimethylsiloxane microﬂuidic chips were manufactured and provided by Fluidigm®
(Fluidigm Corporation, South San Francisco, CA, USA). One is a prototypical
24 reactor chip and the other is a ﬁnal 48 reactor chip. The chips are mounted to a
carrier that facilitates loading of testing and control samples, anti-GFP nanobody
beads, frit beads and the buffers required to perform the on-bead pull-down.
Pressure control and thermocycling were automated using the C1™ system (Flui-
digm®). All reagent and valve control channels were dead-end ﬁlled before script
operation to avoid the presence of air bubbles in the system during the workﬂow.
The procedure is started by loading a mixture of 4.5 and 6.0 µm frit beads packed
into the reactor at 13 psi for 45 s to reduce the size of the reactor exit (5 µm drain
opening size) to enable building of the column. For the 24-parallel reactor chip,
anti-GFP nanobody 2.8 µm beads were packed for 10 min at 13 psi in a 23 nL
reactor to achieve a column size of 5 nL; beads concentration was 15 × 107 beads/
mL in 30% glycerol. On the redesigned 48 parallel reactor ﬁnal chip, beads are
packed in 6 cycles to obtain a column of equal capacity. Bead columns on both
designs were washed with high salt buffer [1M NaCl, 20 mM Hepes pH 7.9, 2 mM
MgCl2, 0.2 mM EDTA, EDTA-free complete proteins inhibitors (Roche®), 1% NP-
40, 0.5 mM DTT]. Washing was performed by building up 11 psi of pressure across
the length of the reactors, then closing the buffer entry channel followed by the
release of the pressure toward a waste container. The columns were washed for 15
cycles before cell extracts were loaded. Whole-cell extract samples were loaded
across the bead columns for 20─60 min using 5─12 psi pressure at 15 °C. All
subsequent washes were also performed using 15 cycles to build up a pressure of
11 psi over the reactor; which guaranteed the transit of approximately three reactor
volumes of buffer to pass through the column. After incubation of the extracts, the
reactors were washed with high salt buffer followed by a wash with PBS, both at 10
°C. To proceed with on-beads protein digestion, the temperature was increased to
37 °C. PBS was displaced by 10 mM DTT in digestion buffer [25 mM ammonium
bicarbonate, 10% acetonitrile], after which the bead columns were incubated with
reduction buffer for 30 min. The chip temperature was increased to 22 °C and
reduction buffer was replaced by alkylation buffer [55 mM iodoacetamide in
digestion buffer], after which the bead columns were incubated with alkylation
buffer for 20 min. After bringing the chip temperature to 37 °C, trypsin buffer
[0.005 µg/µL trypsin (Promega™) in digestion buffer] was introduced and kept in
the reactors for 90 min. Peptides were harvested at 25 °C using 300 cycles of 13 psi
built-up pressure over the length of the chip (approximately, 100 nL volume),
yielding a total of 3–3.5 µL of eluate for each reaction. All valves were locked before
disconnecting and releasing the chip from the C1 device. Eluted peptides were
recovered in PCR tubes compatible with loading into the LC auto sampler for mass
spectrometry.
GFP pull-down protocol in tubes. GFP afﬁnity enrichment was performed using
GFP-Trap®_A beads (ChromoTek). Brieﬂy, 15 µL of beads from a 50% slurry were
washed three times with incubation buffer [300mM NaCl, 20mM HEPES–KOH
(pH 7.9), 20% glycerol, 2 mM MgCl2, 0.2 mM EDTA, EDTA-free complete proteins
inhibitors (Roche®), 1% NP-40, 0.5mM DTT 1% NP-40, 0.5mM DDT]. All washes
were performed by adding 1mL of buffer, rotating the sample 10 times to resuspend
the beads and spinning for 2 min at 1500×g at 4 °C before removal of the buffer.
Beads (7.5 µL) were combined with 500, 100, 20, and 4 µg of whole-cell extract from
SMC1A BAC and HeLaK control cell lines. Incubation was performed in 400 µL ﬁnal
volume of incubation buffer containing ethidium bromide at a ﬁnal concentration of
50 µg/µL for 90min at 4 °C. Beads were then washed twice with a high-salt buffer [1
M NaCl, 20mM Hepes pH 7.9, 2 mM MgCl2, 0.2 mM EDTA, EDTA-free complete
proteins inhibitors (Roche®), 1% NP-40, 0.5 mM DTT], followed by 2 washes with
PBS containing 1% NP-40 and ﬁnally 3 washes with PBS. On-bead digestion of
proteins and the following desalting and puriﬁcation of peptides for mass spectro-
metry analysis were performed as in Baymaz et al.30. Brieﬂy liquid-free beads were
resuspended in 50 µl elution buffer (2M urea, 100mM Tris HCl pH8, 10mM DTT)
and incubated at RT for 20min shaking. After that 50mM iodoacetammide was
added to the bead suspension and incubated for 10min shaking in the dark. 0.25 µg
trypsin (Promega™) were added to the beads suspension and incubated for 2 h at
25 °C shaking vigorously. After incubation time bead suspension was centrifuged,
supernatant was moved to another microcentrifuge tube and beads were washes
again with 50 µl elution buffer and incubated for 5 min shaking. Supernatant con-
taining the digested proteins were combined and 0.1 µg trypsin was added before
over night incubation at RT. Peptide solution was then cleaned over a C18 column
using the stage-tip protocol. In short columns were conditioned with 5 µl methanol
and washed with 20–50 µl 0.1% formic acid in water (FA). Trypsin digestion was
blocked by adding 50 µl of 0.1% FA and 5 µl 5% triﬂuoroacetic acid to reduce pH
conditions. Peptides were then bound to the C18 column, washed with 20–50 µl 0.1%
FA and stored at 4 or −20 °C until mass spectrometry analysis. At that point
peptides were eluted with 30 µl 80% acetonitrile in 0.1% FA and evaporated on a
Concentrator Plus (Eppendorf) using the program V-AQ for 15min and were
reconstituted to a 12 µL volume with 0.1% FA.
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MS and data analyses. Digestion buffer (10 or 25 µL) was added to the on-chip
AP-MS eluted peptides and the solution was incubated overnight at 37 °C in a
wet chamber. Overnight digestion solutions were acidiﬁed by adding 1 µL of 10%
formic acid ﬁrst and diluted with an additional 25 µL of 0.1% formic acid.
Samples were evaporated on a Concentrator Plus (Eppendorf) using the program
V-AQ for 60–100 min and were reconstituted to a 7─8 µL volume with 0.1%
formic acid. Samples were either directly measured with a single injection of 5 µL
on the mass spectrometer or stored at −80 °C until analysis by LC–MS/MS.
Chromatography separations and mass spectrometry analyses were performed
on an Easy-nLC™ 1000 coupled to a LTQ-Orbitrap Fusion™ Tribrid™ (Thermo
Fisher Scientiﬁc). Peptides were separated using an organic gradient obtained by
mixing Buffer A (0.1% formic acid in LC grade water) and Buffer B (80%
acetonitrile, 0.1% formic acid in LC grade water). The linear gradient was
formed over 33 min starting from 15% Buffer B and ending to 35% Buffer B. The
reverse phase column was then washed with 60 and 90% Buffer B for 5 min each
buffer and re-equilibrated to 5% Buffer B for a total acquisition time of 65 min.
The ﬂow rate was 200 nL/min. Analytical columns for reverse phase separations
were packed in house with C18 material [ReproSil-Pur C18-AQ particle size 1.9
µm (Dr. Maisch GmbH, Germany)] in a 300 mm long column spray emitter by
means of an air-pressure pump (Next Advance, Inc.). Emitters were 360 μm OD,
75 μm ID with an opening of 8 ± 1 μm (New Objectives, Inc.). Data were
acquired in data-dependent top speed mode excluding +1 and peptides with
unassigned charge and including charges up to 7+. Peptide full spectra were
recorded from 300 to 1600 m/z on the Orbitrap mass analyzer set at 120 k
resolution in proﬁle mode, using an AGC target of 2E5, a maximum injection
time of 50 milliseconds, and an exclusion time of 1 min. MS/MS spectra were
acquired in the linear ion trap mass analyzer using CID for fragmentation with
a collision energy at 35%, a stepped collision energy of 5; resolution was set to
30 k, AGC target to 1.5E4, scan rate to rapid, and intensity threshold to 5E4.
Data searches were run against SwissProt human database (comprising
reviewed entries only and downloaded in June 2017) using standard settings
on MaxQuant software (version 1.5.1.0). Brieﬂy, 1% false-discovery rate
(FDR) was applied to the match of propensity-score matching and assembly
of proteins. Mass tolerance for correct matches was set to 20 ppm for Fourier
transform mass spectrometry analyzer and 0.5 Da for ion trap mass spectro-
metry MS/MS matches. Carbamidomethylation of cysteines was included as
ﬁxed modiﬁcation while acetyl at protein terminus and methionine oxidation
were considered variable modiﬁcations. Two missed cleavages were allowed
for trypsin enzyme cuts and peptides length was set between 1 and 7 aminoacids.
We performed label free quantiﬁcation with option match between runs
and iBAQ quantiﬁcation of proteins. Perseus software (version 1.5.5.3) was
used to perform ﬁltering, imputation of missing values from a normal dis-
tribution, and permutation-based FDR corrected t test. The data obtained
were visualized by R. Relative stoichiometry of complexes was calculated as in
Smits et al.31. The MS proteomics data have been deposited to the Proteo-
meXchange Consortium via the PRIDE32 partner repository with the dataset
identiﬁer PXD012800.
Reporting Summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data sets generated during and/or analyzed during the current study are available in
the PRIDE repository with the accession number PXD012800 [http://proteomecentral.
proteomexchange.org/cgi/GetDataset?ID= PXD012800].
The source data underlying Figs. 2c, f and 3b and Supplementary Figs. 1e and 2d are
provided as a Source Data ﬁle. A reporting summary for this Article is available as a
Supplementary Information ﬁle. All other data supporting the ﬁndings of this study are
available from the corresponding authors upon reasonable request.
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